Loading
HMPL-306 is an experimental small-molecule drug from Hutchmed in phase 3 trials for acute myeloid leukaemia, aimed at IDH1 / IDH2.
HMPL-306 is a small-molecule drug developed by Hutchmed. Its target is IDH1 / IDH2 (the sponsor names IDH1/IDH2 (mutant)). ClinicalTrials.gov describes the intervention as: Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukaemia), in acute myeloid leukaemia. The largest, NCT06387069, plans to enrol 316 participants with primary completion expected 2028-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Small-molecule drug directed at IDH1 / IDH2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to IDH1 / IDH2.
1.HMPL-306 slips into a pocket on IDH1 / IDH2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HMPL-306" OR ABSTRACT:"HMPL-306" OR TITLE:"HMPL-306 Regimen" OR ABSTRACT:"HMPL-306 Regimen") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HMPL-306, not a curated reading list.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.